Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CORT 108297

Next Previous
Drug Profile

CORT 108297

Alternative Names: ADS-108297; CORT-108297

Latest Information Update: 29 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corcept Therapeutics
  • Developer Corcept Therapeutics; Johns Hopkins University
  • Class 3-ring heterocyclic compounds; Obesity therapies; Pyrazoles; Quinolines; Small molecules; Sulfones
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Cognition disorders; Memory disorders; Post-traumatic stress disorders
  • Discontinued Psychiatric disorders; Weight gain

Most Recent Events

  • 29 Nov 2022 CORT108297 is still in phase II trials for Mild Cognitive impairment, Alzheimer disease, Memory impairment and Post-traumatic stress disorder in USA (NCT04601038) (Corcept therapeutics pipeline, November 2022)
  • 31 Aug 2021 VA Office of Research and Development plans a phase IIa trial for Post-traumatic stress disorders (In adults, In the elderly) in USA (PO) in September 2021 (NCT04452500) (Corcept Therapeutics pipeline, August 2021)
  • 23 Oct 2020 Phase-II clinical trials in Alzheimer's disease (In adults, In the elderly) in USA (PO) (NCT04601038)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top